Skip to main content

Table 3 Hazard ratios of established prognostic parameters and PSCA expression in prostate cancer

From: PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer

Scenario 1 2 3 4
Analyzable (N) 8334 8454 8570 5801
Gleason grade biopsy     
 3 + 4 vs. ≤3 + 3 1.94***    
 4 + 3 vs. 3 + 4 1.63***    
 ≥4 + 4 vs. 4 + 3 1.39***    
cT stage     
 T2a vs. T1c 1.53*** 1.47***   
 T3a vs. T2c 0.65* 1.07   
Preoperative PSA level     
 4–10 vs. < 4 1.25* 1.21* 1.11 1.14
 10–20 vs. 4–10 1.58*** 1.41*** 1.25*** 1.16*
 > 20 vs. 10–20 1.67*** 1.47*** 1.23* 1.22*
PSCA expression     
 Positive vs. negative 0.84*** 0.86** 0.93 0.93
Gleason grade prostatectomy     
 3 + 4 vs. ≤3 + 3   2.91*** 2.39*** 2.30***
 4 + 3 vs. 3 + 4   2.72*** 2.24*** 2.05***
 ≥4 + 4 vs. 4 + 3   1.75*** 1.25* 1.21*
pT stage     
 T3a vs. T2    1.94*** 1.94***
 T3b vs. T3a    1.73*** 1.52***
 T4 vs. T3b    1.20 1.24
Surgical margin (R) status     
 R1 vs. R0    1.40*** 1.18*
 Nodal (pN) stage     
 N+ vs. N0     1.56***
  1. Scenario 1 combines preoperatively available parameter (preoperative Gleason grade obtained on the original biopsy, clinical tumor (cT) stage, and preoperative PSA) with the postoperative PSCA expression. In scenario 2 the biopsy Gleason is replaced by the Gleason grade obtained on radical prostatectomy. In scenario 3 cT stage is superseded by pathological tumor (pT) stage and surgical margin (R) status. In scenario 4 the lymph node (pN) stage is added. Asterisk indicate significance level: * p ≤ 0.05, ** p ≤ 0.001, and *** p ≤ 0.0001